Samsca of Otsuka pharmaceutical was approved in Japan for the treatment of polycystic kidney disease

Source: China Association for the promotion of drugs March 25, 2014, Otsuka Pharmaceutical Co., Ltd announced that samsca (general name: tovaptan) 7.5mg and 15mg tablets were approved in Japan to expand the indications for the treatment of autosomal dominant polycystic kidney disease In addition, samsca 30 mg tablet was also approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Samsca has been developed by many researchers at the Japan Institute of Tokushima for more than 26 years Samsca is currently used as a diuretic in 14 countries and regions around the world It has an antagonistic effect on vasopressin V2 receptor, so only promoting free water excretion will not cause electrolyte loss ADPKD is a genetic disease in which the kidney is enlarged by fluid filled cysts As the disease progresses, renal function declines and then complications occur, including hypertension, hematuria and abdominal pain One in two ADPKD patients aged 70 years will develop to end-stage renal failure, with poor quality of life and poor prognosis As of December 2013, Europe has received and is under review the application of tovaptan for the treatment of ADPKD In the United States, Otsuka has been discussing with the FDA on additional data and re submission path, according to the information released by the FDA Original link: http://www.rttnews.com/2290448/otsuka-pharma-s-samsca-approved-in-japan-for-kidney-disease-adpkd-quick-facts.aspx